A carcinoid tumor of the pancreas (CTP) is a rare pancreatic neoplasm, and usually presents with carcinoid syndrome (CS). CS consists of the classic symptom triad of cutaneous flushing, diarrhea and valvular disease, and occurs in the majority of patients with liver metastases. In the present study, the patient presented with symptoms of CS. A diagnosis of CTP with CS was suspected due to high levels of urine 5-hydroxyindolacetic acid, and this was confirmed by a fine-needle aspiration biopsy. Computed tomography showed extended lymphadenopathy, but no liver metastases. The patient was managed conservatively with octreotide long acting repeatable. To the best of our knowledge, this is the second literature case of CS associated with CTP without liver metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403383 | PMC |
| http://dx.doi.org/10.3892/ol.2017.5678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypointense Findings on Hepatobiliary Phase MR Images.
Radiographics
February 2025
From the Department of Radiology, Division of Abdominal Imaging, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905 (K.C.H., M.L.W., C.L.W., J.F., S.K.V.); Department of Medical Imaging, University of Ottawa, Ottawa, Ontario, Canada (K.C.H.); Department of Medical Imaging, Beaujon University Hospital, Clichy, France (M.R.); HT Medica, Madrid, Spain (A.L.); Department of Radiology, University of Vienna, Vienna, Austria (A.B.S.); Department of Radiology, Sun Yat Sen University, Guangzhou, China (J.W.); and Department of Radiology, Division of Abdominal Imaging, Mayo Clinic, Scottsdale, Ariz (A.C.S.).
Hepatobiliary (HB) contrast agents are increasingly valuable diagnostic tools in MRI, offering a wider range of applications as their clinical use expands. Normal hepatocytes take up HB contrast agents, which are subsequently excreted in bile. This property creates a distinct HB phase providing valuable insights into liver function and biliary anatomy.
View Article and Find Full Text PDFFAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Purpose: To evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [F]FDG PET/CT.
Methods: We prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [Ga]Ga-FAPI-46 or [F]FAPI-42) and [F]FDG PET/CT scans from June 2020 to January 2024 at two medical centers. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI.
Radiomics-based Machine Learning Approach to Predict Chemotherapy Responses in Colorectal Liver Metastases.
J Anus Rectum Colon
January 2025
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Objectives: This study explored the clinical utility of CT radiomics-driven machine learning as a predictive marker for chemotherapy response in colorectal liver metastasis (CRLM) patients.
Methods: We included 150 CRLM patients who underwent first-line doublet chemotherapy, dividing them into a training cohort (n=112) and a test cohort (n=38). We manually delineated three-dimensional tumor volumes, selecting the largest liver metastasis for measurement, using pretreatment portal-phase CT images and extracted 107 radiomics features.
Outcome of Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center.
Indian J Endocrinol Metab
December 2024
Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT). The benefit of Lu-DOTATATE PRRT in patients with progressive metastatic NET was analyzed and survival in multi-organ involvement.
Methods: Forty-one patients with refractory, progressive, or advanced symptomatic NETs, with or without previous treatment modalities were studied.
Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.
Hepat Oncol
December 2024
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis. Survival outcome was compared between groups with immunotherapy and groups without immunotherapy. Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!